ADXS (Ayala Pharmaceuticals) Risk Assessment

View and export this data going back to 2020. Start your Free Trial

What is Ayala Pharmaceuticals Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Ayala Pharmaceuticals is: No Data: Cannot be evaluated.

Competitive Comparison of Ayala Pharmaceuticals's Risk Assessment

For the Biotechnology subindustry, Ayala Pharmaceuticals's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ayala Pharmaceuticals's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ayala Pharmaceuticals's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Ayala Pharmaceuticals's Risk Assessment falls into.

Save Embed

;

Save Embed

;

Ayala Pharmaceuticals (OTCPK:ADXS) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Ayala Pharmaceuticals Risk Assessment Related Terms

Thank you for viewing the detailed overview of Ayala Pharmaceuticals's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Ayala Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ayala Pharmaceuticals Inc (OTCPK:ADXS) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

9 Deer Park Drive, Suite K-1, Monmouth Junction, NJ, USA, 08852

Website

https://www.ayalapharma.com

Ayala Pharmaceuticals Inc is a clinical-stage oncology company whose primary clinical assets currently include aspacytarabine (BST-236), a novel proprietary anti-metabolite for first-line treatment in unfit acute myeloid leukemia (AML). BST-236 is a novel prodrug of cytarabine, enabling the delivery of high cytarabine doses with reduced systemic toxicity, creating a potential new backbone for AML combination regimens. It believes that its novel product candidates if approved, have the potential to transform treatment outcomes for patients suffering from solid and hematological cancers. These efforts are primarily focused on the development of ADXS-504, an Lm-based therapy for early-stage prostate cancer.

Executives

Yair Chaim Schindel	other: shareholder of 10% holder	YERUSHALAYIM ROAD 34, BEIT GAMLA ENTRANCE B, RA'ANANA L3 4350110
Roni Mamluk	director, officer: CEO	CHIASMA, INC., 60WELLS AVENUE, NEWTON MA 02459
Gary B. Gordon	officer: Chief Medical Officer	C/O AYALA PHARMACEUTICALS, INC., OPPENHEIMER 4, REHOVOT L3 7670104
David Sidransky	director	JOHNS HOPKINS UNIVERSITY, 720 RUTLAND AVENUE, BALTIMORE MD 21205
Vered Bisker-leib	director	C/O COMPASS, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Israel Biotech Fund I, L.p.	10 percent owner	4 OPPENHEIMER ST., REHOVOT L3 7670104
Harel Insurance Co Ltd	10 percent owner	ABBA HILLEL 3, RAMAT GAN L3 5211802
Amoon Growth Fund Limited Partnership	10 percent owner	34 YERUSHALAYIM RD., RAANANA L3 4350110
Murray A Goldberg	director	2030 MAIN STREET, SUITE 1500, IRVINE CA 92614
Maimon Yossi	officer: CFO	C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT ST, SCIENCE PARK, POB 455, CARMIEL L3 20100
Robert J. Spiegel	director	C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Harel Insurance Investments & Financial Services Ltd.	10 percent owner	HAREL HOUSE, 3 ABBA HILLEL ST., RAMAT GAN L3 52118
Todd Sone	director	C/O AYALA PHARMACEUTICALS, INC., OPPENHEIMER 4, REHOVOT L3 7670104